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htticense.Abstract Aim of work: To explore the inﬂuence of the presence of concomitant ﬁbromyalgia
(FM) on the evaluation of disease activity score assessing 28 joints (DAS28), clinical disease activity
index (CDAI) and modiﬁed health assessment questionnaire (MHAQ) in Egyptian patients with
rheumatoid arthritis (RA).
Patients and methods: This study included 50 female RA patients; out of which 25 had concom-
itant FM (RAF group), the other 25 RA patients who served as controls did not have concomitant
FM (RA group). All patients were subjected to an assessment of disease activity using the DAS 28
and the CDAI and assessment of functional outcome using MHAQ score.
Results: The mean DAS 28 was signiﬁcantly higher in RAF than RA patients (5.6 ± 1.1 versus
4.5 ± 1.3, P= 0.009). Also, the mean CDAI score was signiﬁcantly higher in the RAF group
(mean 23.3 ± 12.1 versus 13.7 ± 11.0, P= 0.002). The difference was attributed to signiﬁcantly
higher subjective items such as Tender joint count (TJC) and patient’s global assessment of general
health (VAS-GH) in the RAF group. Mean MHAQ score was also higher in the RAF group
(0.7 ± 0.6 versus 0.31 ± 0.4, P= 0.006).
Conclusion: FM is related to worse scores on the DAS28, CDAI and MHAQ in patients with
RA. The presence of FM may have major implications in the interpretation of the DAS28 and
CDAI scores because it is related to higher scores independently of objective evidence of RA activ-
ity.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis. Open access under CC BY-NC-ND license.Box 109, Cairo 11559, Egypt.
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Fibromyalgia (FM) is a chronic, musculoskeletal, non inﬂam-
matory pain disorder. Patients frequently suffer from sleep dis-
turbances, headaches, anxiety, morning stiffness, and a poor
sense of well-being. It is characterized by the presence of at
least 11 tender points, as well as widespread bilateral pain
for at least 3 months [1]. FM occurs in 1–4% of the normal
population, but has a much higher prevalence in rheumatic dis-gyptian Society for Joint Diseases and Arthritis.
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116 Z. Nawito et al.eases [2]. In patients with rheumatoid arthritis (RA), concom-
itant FM has been reported in 10–20% of cases and may rep-
resent an additional factor that worsens pain, physical, social
and emotional limitations in these patients [3,4].
Disease remission is now considered a realistic goal for
many RA patients. Measures of outcome such as composite
indices of disease activity and questionnaires for functional
status, facilitate clinical decision making to achieve this goal,
and studies in RA show that treating to target improves out-
comes [5,6]. However, previous studies [7–10] found that pa-
tients with RA and concomitant FM (RAF) have worse
scores on Disease Activity Score in 28 joints (DAS28) and
Health Assessment Questionnaire (HAQ), independent of
objective evidence of RA activity which could lead to an unjus-
tiﬁed increase of the burden of treatment with risk of adverse
events and higher cost in this subset of RA patients. Thus this
study was conducted to evaluate the impact of ﬁbromyalgia on
two composite indices of disease activity: DAS 28 and clinical
disease activity index (CDAI) as well as on functional outcome
using Modiﬁed Health Assessment Questionnaire (MHAQ)
score among a cohort of Egyptian RA patients.
2. Patients and methods
Out of 150 consecutive RA patients screened at the outpatient
clinic of the Rheumatology and Rehabilitation Department,
Faculty of Medicine, Cairo University who fulﬁlled the 2010
ACR criteria for diagnosis of RA [11], ﬁfty were recruited to
the study. Twenty-ﬁve patients who concomitantly fulﬁlled
the ACR criteria for diagnosis of FM [12] were selected as
the ﬁrst group (RAF). They were all females. Another 25 fe-
male RA patients of matching age served as the control group
(RA). They did not have concomitant FM with a tender point
count (TPC) using manual point survey of <6 points. The cut
off of P6 TPC better discriminates patients with FM from
those without FM in clinical practice [13]. Excluded from
our study were RA patients with other causes of widespread
pain as endocrinopathies, end stage liver or kidney disease,
major psychiatric disorders or metabolic bone disease. All pa-
tients gave their informed consent and the study was approved
by the local ethics committee.
All studied patients were subjected to full history taking,
thorough clinical examination and routine laboratory investi-
gations. Plain radiographs were done for hands and wrists.
Assessment of disease activity was done using two scores: the
DAS 28 [14] with its components, tender (TJC) and swollen
joint counts (SJC), visual analog scale for patient’s global
assessment of general health (VAS-GH scored 0–100 mm),
and erythrocyte sedimentation rate (ESR in mm/ﬁrst hour),
as well as the CDAI score which is based on the simple sum-
mation of the count of swollen and tender joint count of 28
joints along with VAS-GH and physician global assessment
(VAS-PH) [15]. Assessment of functional outcome was done
using MHAQ score [16]. Types and doses of medications were
recorded for each patient group.
Statistical analysis: Data were analyzed using the computer
program, SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Win-
dows. Data were described in terms of mean ± standard devi-
ation (±SD), frequencies (number of cases) and percentages
when appropriate. Comparison of quantitative variables be-tween the study groups was done using Mann Whitney U test
for independent samples. For comparing categorical data, Chi
square (v2) test was performed. Exact test was used instead
when the expected frequency was <5. A probability value (P
value) <0.05 was considered statistically signiﬁcant.
3. Results
The demographic and clinical characteristics of patients with
and without FM shown in Table 1 were not signiﬁcantly differ-
ent. Regarding somatic symptoms of ﬁbromyalgia, all except
morning stiffness, dysmenorrhea and irritable bowel syndrome
were signiﬁcantly higher in the RAF group as shown in
Table 2.
On comparing disease activity scores in the studied popula-
tion, we found that mean DAS 28 was signiﬁcantly higher in
the RAF compared to the non-ﬁbromyalgia group
(5.6 ± 1.1.16 versus 4.5 ± 1.3, P= 0.009). Also, mean CDAI
score was signiﬁcantly higher in the RAF group (23.3 ± 12.1
versus 13.7 ± 11.0, P= 0.002).This signiﬁcant statistical dif-
ference was related to the subjective components of DAS28
and CDAI (TJC and VAS -GH) while no signiﬁcant difference
was found in SJC, ESR or VAS-PH as shown in Table 3. The
TJC and SJC were positively correlated in the non-ﬁbromyal-
gia group (P= 0.001). However in RAF group they were
poorly correlated (P= 0.993) (Figs. 1 and 2).The distribution
of our RA patients among different disease activity grades of
both DAS28 and CDAI is demonstrated in Table 4.
Regarding MHAQ score, its mean in the RAF group was
signiﬁcantly higher than in the non-ﬁbromyalgia group
(0.7 ± 0.6 versus 0.31 ± 0.4, P= 0.006).
As shown in Table 5, the number of patients receiving ste-
roids as well as their mean steroid cumulative dose were higher
in the RAF group but the difference reached statistical signif-
icance for the dose only (P= 0.005). On the other hand, the
number of patients using methotrexate was higher in the
non-ﬁbromyalgia group while leﬂunomide was used by more
patients in the RAF group and the difference was statistically
signiﬁcant as regards patients’ number (P= 0.005 and 0.008
respectively) but no signiﬁcant difference was found in drug
doses. The number of patients using chloroquine and its dose
was comparable in both groups (P= 0.157).
4. Discussion
In the present study, all recruited patients were females. Previ-
ous studies have shown a higher prevalence of RAF among
women [3,4,8,10]. As we chose to have both patient groups
comparable in age, sex and disease duration, it was not possi-
ble to study these factors as risk factors. Although the BMI of
RAF patients studied was higher than RA patients the differ-
ence was statistically insigniﬁcant. In the studies of Coury and
colleagues [7] and Dhir and colleagues [2] the BMI of RAF
population was signiﬁcantly higher than the BMI of the RA
population.
Morning stiffness which is a hallmark of rheumatoid arthri-
tis is also considered one of the somatic symptoms of ﬁbromy-
algia. In our study, both the prevalence and duration of
morning stiffness were higher in the RAF group but the differ-
ence was statistically insigniﬁcant. Morning stiffness duration
was signiﬁcantly longer in RAF patients in the studies of Cou-
Table 1 Demographic and clinical data of studied rheumatoid arthritis patients.
Patients P value
RAF (no = 25) RA (no = 25)
Age (years) 42.6 ± 10.2 45.3 ± 11.5 0.34
BMI 31.2 ± 5.7 29.3 ± 5.9 0.14
Disease duration (years) 9.5 ± 6.5 7.5 ± 7.1 0.15
Morning Stiﬀness duration (min) 18 ± 21.9 12.4 ± 20.6 0.2
Extraarticular features: no (%) 4 (16%) 4 (16%) 1.00
Deformities: no (%) 10 (40%) 7 (28%) 0.37
Rheumatoid factor positivity: no (%) 19 (76%) 19 (76%) 1.00
Erosive changes in X-ray: no (%) 14 (56%) 16 (66.7%) 0.44
RAF: rheumatoid arthritis with concomitant ﬁbromyalgia, RA: rheumatoid arthritis, BMI: body mass index. Results are presented as
mean ± SD and no (%).
Table 2 Somatic manifestations of studied rheumatoid arthritis patients.
Somatic manifestations percentage (%) Patients P value
RAF (25) RA (25)
Widespread pain 100 28 <0.001
Sleep disturbance 68 32 0.011
Fatigue 92 52 0.002
Morning stiﬀness 56 36 0.156
Headache 56 24 0.021
Depression 88 40 <0.001
Anxiety 72 40 <0.001
Parasthesia 76 32 0.002
Cognitive symptoms 56 16 0.003
Dysmenorrhea 20 20 1
Irritable bowel syndrome 16 4 0.157
RAF: rheumatoid arthritis with concomitant ﬁbromyalgia, RA: rheumatoid arthritis.
Table 3 Disease activity assessment scores and their individ-
ual components in studied rheumatoid arthritis patients.
Disease activity components Patients P-Value
RAF (25) RA (25)
Tender joint count 12.3 ± 9.1 4.5 ± 4.2 0.01
Swollen joint count 2.8 ± 3.2 3 ± 4.1 0.96
ESR (mm/h) 38.2 ± 16.8 41.8 ± 22.5 0.53
Patient VAS (mm) 64 ± 23.6 46.8 ± 25.9 0.019
Physician VAS (mm) 18.8 ± 16.6 16.6 ± 16.7 0.345
DAS 28 5.6 ± 1.1 4.5 ± 1.3 0.009
CDAI 23.3 ± 12.1 13.7 ± 11.0 0.002
MHAQ 0.7 ± 0.6 0.31 ± 0.4 0.006
RAF: rheumatoid arthritis with concomitant ﬁbromyalgia, RA:
rheumatoid arthritis. ESR: erythrocyte sedimentation rate, VAS:
visual analog scale, DAS28: disease activity score in 28 joints,
CDAI: clinical disease activity index, MHAQ: modiﬁed health
assessment questionnaire.
Figure 1 Correlation between tender joint count (TJC) and
swollen joint count (SJC) in non ﬁbromyalgic rheumatoid arthritis
(RA) patients.
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longed morning stiffness in RAF patients was explained by
pain, fatigue, and sleep disturbance.
The mean DAS 28 in the present study was signiﬁcantly
higher in the RAF group. The difference was attributed to
the subjective measures of the score: the tender joint count
and VAS-GH which were signiﬁcantly higher in the ﬁbromyal-gic group. The objective measures on the other hand: swollen
joint count and ESR were found to be comparable (statistically
insigniﬁcant difference) in both groups. Similar results were re-
ported by Ton and colleagues [9], Ranzolin and colleagues [8]
and Vilaseca and Oteroin [17]. In our study as well as that con-
ducted by Dhir and colleagues [2] the TJC and SJC were signif-
icantly positively correlated in the RA group while in the RAF
Figure 2 Correlation between tender joint count (TJC) and
swollen joint count (SJC) in ﬁbromyalgic rheumatoid arthritis
(RAF) patients.
Table 4 Classiﬁcation of disease activity in studied RA
patients according to the disease activity indices (DAS 28 and
CDAI).
Disease activity Patients
RAF (25) RA (25)
DAS28
High (DAS28 > 5.1). 16 (64%) 7 (28%)
Moderate (3.2 < DAS28P 5.1) 9 (36%) 14 (56%)
Low (DAS28 6 3.2) 0 (0%) 3 (12%)
Remission (DAS < 2.6) 0 (0%) 1 (4%)
CDAI
High (CDAI > 22) 10 (40%) 6 (24%)
Moderate (10 < CDAI 6 22) 12 (48%) 8 (32%)
Low (2.8 < CDAI 6 10) 3 (12%) 10 (40%)
Remission (CDAI 6 2.8) 0 (0%) 1 (4%)
RAF: rheumatoid arthritis with concomitant ﬁbromyalgia, RA:
rheumatoid arthritis.DAS28: disease activity score in 28 joints,
CDAI: clinical disease activity index.
118 Z. Nawito et al.group they were poorly correlated. But in their study, both the
TJC and SJC were signiﬁcantly higher in the RAF group. Cou-
ry and associates [7] also reported higher SJC in RAF patients
using the ACR joint count including 66 joints which were par-
tially due to a higher swollen metatarsophalangeal joint count
in patients with RAF. This count is known to be difﬁcult to
assess, especially in obese patients, who were more numerous
in their RAF group, as shown by BMI.Table 5 Comparison of types and doses of medications received by
Steroids (gm/ intake) MTX (m
RAF No (%) 15 (60%) 13 (52%)
Dose 5.4 ± 11.7 20.2 ± 4
RA No (%) 9 (36%) 22 (88%)
Dose 2.0 ± 0.4 19.4 ± 4
P No 0.089 0.005
Value Dose 0.005 0.544
RAF: rheumatoid arthritis with concomitant ﬁbromyalgia, RA: rheumatRegarding the mean CDAI score in the present study, it
was found to be signiﬁcantly higher in the RAF group. Like
DAS 28, the difference was attributed to the higher subjective
measures of the score: the tender joint count and VAS-GH
while the swollen joint count and VAS-PH were comparable.
The use of CDAI in our study was considered as an alternative
to DAS28 in assessment of RAF patients owing to the hypoth-
esis that unlike DAS28 where TJC receives double the weigh-
ing received by SJC, in CDAI both items are weighed equally.
However, it showed no advantage over DAS28 in avoiding
overestimation of disease activity in RAF. This could be ex-
plained by the fact that in the CDAI, VAS-GH receives a high-
er weight than in DAS28. On the other hand, it does not
include an acute phase reactant, one of the objective measures
of disease assessment used in DAS28. This agrees with the
study of Pollard and colleagues [18].
Functional assessment of patients was performed in the
present study using the MHAQ score. Our results revealed that
its mean in the RAF group was signiﬁcantly higher than the
RA group. These results came in accordance with previous
studies [2,4,7,8] which reported a worse functional outcome as-
sessed using HAQ -DI. Proposed explanation was that FM per
se has been described as being related to a worse functional
outcome similar to that observed in RA.
Regarding the treatment of our studied patients, the num-
ber of patients receiving steroids and the cumulative steroid
dose were both higher in the RAF group with a signiﬁcant sta-
tistical difference regarding steroid cumulative dose. These re-
sults are in accordance with those of Ranzolin and colleagues
[8]. This may reﬂect a response to the higher disease activity
indices reported in RAF patients. However, Dhir and col-
leagues [2] found no difference when it came to steroids as re-
gards the number of patients using them and dosage.
Hence as proved in our study and other studies, DAS28 as
well as the CDAI overestimate disease activity in RAF pa-
tients. Therefore, the possibility that FM affects the interpreta-
tion of this score may have important implications. In routine
clinical practice, misclassiﬁcation of disease activity may lead
to an unnecessary change in the therapy of RA. It may affect
the selection of patients in clinical trials, because a high DAS28
score is frequently used as one of the inclusion criteria. The
interpretation of results may also be affected, considering that
FM symptoms are not expected to respond to therapeutics di-
rected toward RA.
5. Conﬂict of Interest
None.studied rheumatoid arthritis patients.
g/week) Leﬂunomide (mg/day) Chloroquine (mg/day)
11 (44%) 4 (16%)
.4 20 ± 0.0 250 ± 0.0
2 (8%) 1 (4%)
.2 20 ± 0.0 250 ± 0.0
0.008 1
0.157 1
oid arthritis. MTX: methotrexate.
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